A Phase 2/3 interventional study of Humalog and Novolog in Type 1 Diabetes Mellitus, sponsored by Massachusetts General Hospital. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-09.
Sponsored by Massachusetts General Hospital · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 52nd largest by enrollment, is one of 10 that started in 2019, is the only one in phase 2/3, and was the 38th registered.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 7–18
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 18–99
Tel-Aviv Sourasky Medical Center · Sites in Israel
Ages 18+
By country, each count listing its studies:
Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 9 · Phase 3 14 · Phase 4 12
First in 2002; this study’s year is marked. 10 started in 2019.
This study's enrollment of 20 is below the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 69 interventional studies. Of the 60 that completed or were terminated, 33 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 69 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,590 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
28 studies in Diabetes Mellitus, Type 1 by Massachusetts General Hospital: 1 open now, 4 under way, none of them phase 3. Of 21 finished, 16 (76%) have results posted.
Among the 28 studies in Diabetes Mellitus, Type 1 by Massachusetts General Hospital, this one is the 17th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2019, is one of 2 in phase 2/3, and was the 20th registered.
Massachusetts General Hospital’s Diabetes Mellitus, Type 1 studies by the year they started, since 2005.
1 of the studies testing Insulin Lispro in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, from their registry updates:
Among Massachusetts General Hospital’s 28 in Diabetes Mellitus, Type 1:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Subjects will participate in three weeks of the bionic pancreas in the insulin-only configuration. Each week, subjects will use a different rapid acting insulin analog -- Humalog, Novolog, or BC222 insulin lispro -- in a randomized cross-over order.
The investigators hypothesize that differences in the PK characteristics of insulin analogs will lead to differences in glycemic outcomes when delivered by the insulin-only configuration of the bionic pancreas. Specifically, the investigators predict that insulin analogs that have faster absorption (numerically lower Tmax and/or T½max) and insulin analogs that have faster clearance (numerically lower terminal half-life) will result in lower mean glucose and/or a lower percentage of time in the hypoglycemic range.
Up to 30 subjects will participate in three 7-day study arms using insulin lispro, insulin aspart, and BC222 lispro in the bionic pancreas in random order. The co-primary outcomes will be mean CGMG and fraction of time spent with CGMG \<54 mg/dl with comparisons made between arms for individual participants. Secondary analyses will include time in glycemic ranges (\<50, \<60, \<70, 70-120, 70-180, >180, >250 mg/dl), coefficient of variation, mean postprandial excursion (difference in CGMG from the time of meal announcement to the peak CGMG in the first 4 hours after the meal announcement) for both mixed meal challenges, number of symptomatic hypoglycemic events, grams of carbohydrate consumed to treat hypoglycemia, and TDD of insulin, between arms for individual subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Acceptable contraception methods include: Oral contraceptive pill (OCP), Intrauterine Device (IUD, hormonal or copper), Male condoms, Female condoms, Diaphragm or cervical cap with spermicide, Contraceptive patch (such as OrthoEvra), Contraceptive implant (such as Implanon, Nexplanon), Vaginal ring (such as NuvaRing), Progestin shot (such as Depo-Provera), Male partner with a vasectomy proven to be effective by semen analysis
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
Drug: Humalog · Device: Bionic Pancreas
Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
Drug: Novolog · Device: Bionic Pancreas
Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
Drug: BC222 insulin lispro · Device: Bionic Pancreas
Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
Also known as: insulin
Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
Also known as: insulin
Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
Also known as: insulin
The insulin-only bionic pancreas will be used in all three arms of the study
Average Continuous Glucose Monitor (CGM) Glucose
The average glucose achieved by the bionic pancreas as measured by the continuous glucose monitor during each arm
Time frame: 7 days
Percentage of Time Spent With CGM Glucose < 54 mg/dl
The amount of time the subject spent in the hypoglycemic range \< 54 mg/dl as measured by the continuous glucose monitor during each arm
Time frame: 7 days
Percentage of Time Spent Within Each of the Following Ranges:
The amount of time subject's spent in each of the listed glucose ranges as measured by the continuous glucose monitor during each bionic pancreas arm
Time frame: 7 days
Within Day Coefficient of Variation
A measure of dispersion of glucose values around the mean
Time frame: 7 days
Mean Post Prandial Excursion
Difference in CGMG from the beginning of the meal challenge to the peak CGMG in the 4 hours after the meal, for both mixed meal challenges.
Time frame: 7 days
Number of Symptomatic Hypoglycemic Events Per Day
The number of times subjects report experiencing symptoms of hypoglycemia during each bionic pancreas arm
Time frame: 7 days
Grams of Carbohydrates Consumed to Treat Hypoglycemia Per Day
The total amount of grams of carbohydrates subjects report having to take in for treatment of hypoglycemia
Time frame: 7 days
Total Daily Dose of Insulin
The average total amount of insulin delivered daily by the bionic pancreas during each bionic pancreas arm.
Time frame: 7 days
| Milestone | Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Lispro, Then Insulin Aspart | Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Aspart, Then Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Lispro, Then BC222 Lispro, Then Insulin Aspart | Insulin-only Bionic Pancreas With Insulin Lispro, Then Insulin Aspart, Then BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Aspart, Then BC222 Lispro, Then Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart, Then Insulin Lispro, Then BC222 Lispro |
|---|---|---|---|---|---|---|
| Started | 2 | 3 | 2 | 2 | 2 | 2 |
| Completed | 2 | 1 | 1 | 1 | 1 | 0 |
| Not completed | 0 | 2 | 1 | 1 | 1 | 2 |
| Withdrew: Physician decision | 0 | 2 | 1 | 1 | 1 | 2 |
The average glucose achieved by the bionic pancreas as measured by the continuous glucose monitor during each arm
| mg/dl | Insulin-only Bionic Pancreas With BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart |
|---|---|---|---|
| Average Continuous Glucose Monitor (CGM) Glucose | 157.0 ± 9.2 | 151.4 ± 13.1 | 151.2 ± 13.8 |
The amount of time the subject spent in the hypoglycemic range \< 54 mg/dl as measured by the continuous glucose monitor during each arm
| percentage of CGM glucose values | Insulin-only Bionic Pancreas With BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart |
|---|---|---|---|
| Percentage of Time Spent With CGM Glucose < 54 mg/dl | 0.30 ± 0.53 | 0.55 ± 0.26 | 1.01 ± 0.70 |
The amount of time subject's spent in each of the listed glucose ranges as measured by the continuous glucose monitor during each bionic pancreas arm
| percentage of CGM glucose values | Insulin-only Bionic Pancreas With BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart |
|---|---|---|---|
| % time CGM glcuose < 50 mg/dl | 0.20 ± 0.42 | 0.24 ± 0.21 | 0.63 ± 0.50 |
| % time CGM glcuose < 60 mg/dl | 0.80 ± 0.88 | 1.31 ± 0.55 | 1.85 ± 1.05 |
| % time CGM glcuose < 70 mg/dl | 2.65 ± 1.71 | 3.59 ± 1.71 | 4.31 ± 1.66 |
| % time CGM glcuose 70-120 mg/dl | 27.49 ± 5.04 | 27.20 ± 5.53 | 30.44 ± 5.57 |
| % time CGM glcuose 70-180 mg/dl | 67.77 ± 8.57 | 72.16 ± 10.34 | 70.06 ± 10.25 |
| % time CGM glcuose >180 mg/dl | 29.58 ± 7.79 | 24.26 ± 9.29 | 25.63 ± 9.02 |
| % time CGM glcuose > 250 mg/dl | 7.67 ± 3.55 | 5.21 ± 5.24 | 7.11 ± 6.41 |
A measure of dispersion of glucose values around the mean
| percentage of CGM glucose values | Insulin-only Bionic Pancreas With BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart |
|---|---|---|---|
| Within Day Coefficient of Variation | 37.4 ± 4.1 | 35.5 ± 7.8 | 38.6 ± 7.8 |
Difference in CGMG from the beginning of the meal challenge to the peak CGMG in the 4 hours after the meal, for both mixed meal challenges.
| mg/dl | Insulin-only Bionic Pancreas With BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart |
|---|---|---|---|
| Mean Post Prandial Excursion | 95.06 ± 37.49 | 103.13 ± 47.37 | 104.07 ± 36.60 |
The number of times subjects report experiencing symptoms of hypoglycemia during each bionic pancreas arm
| number of events | Insulin-only Bionic Pancreas With BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart |
|---|---|---|---|
| Number of Symptomatic Hypoglycemic Events Per Day | 0.73 ± 0.43 | 0.60 ± 0.43 | 1.02 ± 0.67 |
The total amount of grams of carbohydrates subjects report having to take in for treatment of hypoglycemia
| grams of carbohydrates | Insulin-only Bionic Pancreas With BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart |
|---|---|---|---|
| Grams of Carbohydrates Consumed to Treat Hypoglycemia Per Day | 12.42 ± 11.59 | 9.27 ± 6.94 | 14.00 ± 11.95 |
The average total amount of insulin delivered daily by the bionic pancreas during each bionic pancreas arm.
| units per kilogram per day | Insulin-only Bionic Pancreas With BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart |
|---|---|---|---|
| Total Daily Dose of Insulin | 0.71 ± 0.16 | 0.60 ± 0.21 | 0.61 ± 0.25 |
Collected over 1 week of study participation using each insulin, for a total of up to three weeks of study intervention. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin-only Bionic Pancreas With BC222 Lispro | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Insulin-only Bionic Pancreas With Insulin Lispro | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Insulin-only Bionic Pancreas With Insulin-aspart | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
20 participants consented to participate. 13 participants were randomized to complete three weeks using the insulin-only bionic pancreas. Only 6 completed all three arms. The numbers listed in the participant flow, and throughout the record only represent unique participants. Dyads, including designated contacts, are not used. No data was collected from designated contacts that is relevant to this protocol.
| Age, Continuous(years) | Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Lispro, Then Insulin Aspart | Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Aspart, Then Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Lispro, Then BC222 Lispro, Then Insulin Aspart | Insulin-only Bionic Pancreas With Insulin Lispro, Then Insulin Aspart, Then BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Aspart, Then BC222 Lispro, Then Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart, Then Insulin Lispro, Then BC222 Lispro | Total |
|---|---|---|---|---|---|---|---|
| Mean | 30.0 ± 14.1 | 40.7 ± 17.6 | 70.5 ± 14.8 | 33.0 ± 9.9 | 47.0 ± 14.1 | 50.0 ± 15.6 | 47.8 ± 15.9 |
| Sex: Female, Male(Participants) | Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Lispro, Then Insulin Aspart | Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Aspart, Then Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Lispro, Then BC222 Lispro, Then Insulin Aspart | Insulin-only Bionic Pancreas With Insulin Lispro, Then Insulin Aspart, Then BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Aspart, Then BC222 Lispro, Then Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart, Then Insulin Lispro, Then BC222 Lispro | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 2 | 1 | 2 | 1 | 1 | 7 |
| Male | 2 | 1 | 1 | 0 | 1 | 1 | 6 |
| Race (NIH/OMB)(Participants) | Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Lispro, Then Insulin Aspart | Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Aspart, Then Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Lispro, Then BC222 Lispro, Then Insulin Aspart | Insulin-only Bionic Pancreas With Insulin Lispro, Then Insulin Aspart, Then BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Aspart, Then BC222 Lispro, Then Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart, Then Insulin Lispro, Then BC222 Lispro | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 2 | 3 | 2 | 2 | 1 | 2 | 12 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Lispro, Then Insulin Aspart | Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Aspart, Then Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Lispro, Then BC222 Lispro, Then Insulin Aspart | Insulin-only Bionic Pancreas With Insulin Lispro, Then Insulin Aspart, Then BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Aspart, Then BC222 Lispro, Then Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart, Then Insulin Lispro, Then BC222 Lispro | Total |
|---|---|---|---|---|---|---|---|
| United States | 2 | 3 | 2 | 2 | 2 | 2 | 13 |
| Hemoglobin A1c(percent of glycated hemoglobin) | Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Lispro, Then Insulin Aspart | Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Aspart, Then Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Lispro, Then BC222 Lispro, Then Insulin Aspart | Insulin-only Bionic Pancreas With Insulin Lispro, Then Insulin Aspart, Then BC222 Lispro | Insulin-only Bionic Pancreas With Insulin Aspart, Then BC222 Lispro, Then Insulin Lispro | Insulin-only Bionic Pancreas With Insulin Aspart, Then Insulin Lispro, Then BC222 Lispro | Total |
|---|---|---|---|---|---|---|---|
| Mean | 6.7 ± 0.8 | 6.9 ± 0.9 | 6.9 ± 0.2 | 6.2 ± 0.5 | 7.2 ± 0.8 | 6.4 ± 0.5 | 6.7 ± 0.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Mar 2019 to primary completion in Jul 2019, 4 months.
Results were first posted in Dec 2022, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Lispro · Insulin Aspart · Insulin
Massachusetts General Hospital →